Aumolertinib Phase 3 Study Meets Primary Endpoint in First-Line Treatment for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

2.22.2021

Download

Aumolertinib Phase III Study Meets Primary Endpoint in First-Line Treatment for Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer

EQRx, a company committed to developing and delivering important new medicines at lower prices, announced that its partner, Hansoh Pharmaceuticals, has disclosed topline results of its Phase III study of epidermal growth factor receptor (EGFR) inhibitor, aumolertinib, in the first-line setting. The study showed that aumolertinib met its primary endpoint in first-line treatment of patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). The companies plan to present the detailed results of the study at an upcoming international medical conference.

“The financial toxicity of lung cancer treatment can be devastating to patients and families and have a significant effect on optimal care. Access to more affordable, high-quality therapeutic options is vital to improving adherence and outcomes,” said Vincent Miller, M.D., physician-in-chief of EQRx. “This positive top-line data reflects the potential for aumolertinib to have a meaningful impact on patient care as a more affordable treatment option in the first-line treatment of a large subset of NSCLC.”

EQRx is responsible for the development and commercialization of aumolertinib in the United States, European Union, United Kingdom, Japan and global markets outside of Greater China. EQRx and Hansoh will seek to jointly conduct global studies to further expand the potential of aumolertinib as a monotherapy and in combination therapy settings. Aumolertinib is currently approved in China for patients with EGFR mutant NSCLC and EGFRT790M upon progression of disease on prior EGFR tyrosine kinase inhibitor therapy and is marketed under the name Ameile® by Hansoh Pharmaceuticals.

About Aumolertinib

Aumolertinib (proposed international nonproprietary name, formerly almonertinib) is a novel, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) with

favorable pharmacologic properties that selectively inhibits both EGFR sensitizing and resistance mutations. Aumolertinib tablets, 110mg once-daily, have been approved by the National Medical Products Administration in China as a medicine indicated for the treatment of patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after prior EGFR TKI therapy.

About the study

The study is a Phase III, randomized, controlled, double-blind, multicenter trial of aumolertinib versus gefitinib as first-line treatment for patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.

About EQRx

EQRx is committed to catalyzing a market-based solution to one of society's biggest healthcare challenges by developing important new medicines and offering them at lower prices. Through strategic partnerships with stakeholders from across the healthcare system and cutting-edge science and technology, the Company aims to provide high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. EQRx is a purpose-built disruptor at scale, remaking medicine to bend the cost curve in drug pricing. To learn more, visit www.eqrx.com and follow us on social media:
Twitter: @EQRx_GLOBAL, LinkedIn, Instagram: @eqrxinc.

Media Contact:
Meggan Buckwell
media@EQRx.com